Human D-amino acid oxidase (hDAAO), the flavoenzyme that degrades the NMDA-receptor co-agonist D-serine in the brain, binds its FAD cofactor exceptionally weakly (Kd≈8 μMK_d \approx 8\,\mu\mathrm{M}, close to estimated brain FAD levels), so the enzyme is expected to sit near a holoenzyme/apoprotein equilibrium in the cell, with the inactive apoprotein favored unless an active-site ligand tightens cofactor binding. The 2009 study that established this biophysical picture left open how this equilibrium operates in vivo: no three-dimensional structure of the apoprotein exists, the intracellular fraction of active holoenzyme has never been quantified, the endogenous ligands that drive holoenzyme formation in brain are unidentified, the slow Holo*-to-holoenzyme conformational isomerization observed during reconstitution lacks a molecular description, and the mechanism by which the primate-specific protein pLG72 accelerates hDAAO inactivation and degradation is only partially understood. This problem asks for a cellular and molecular account connecting the in vitro weak-flavin-binding picture to the in vivo regulation of D-serine metabolism. As of 2026 the pLG72 arm is understood at the cellular level (induced destabilization and accelerated proteasomal degradation of cytosolic hDAAO, with cofactor affinity unchanged), whereas the apoprotein structure, in vivo cofactor occupancy, endogenous ligand identity, and the atomic mechanisms of both the slow isomerization step and of pLG72 action remain open.

Background

D-amino acid oxidase (DAAO; EC 1.4.3.3) is a flavoenzyme (an enzyme whose catalysis requires a flavin cofactor) that catalyzes the oxidative deamination of D-amino acids to the corresponding alpha-keto acids, hydrogen peroxide, and ammonia. In the human brain it is the main catabolic enzyme for D-serine, a gliotransmitter (a signaling molecule released by glial cells) that serves as an endogenous co-agonist of the N-methyl-D-aspartate type glutamate receptor (NMDAR); excessive D-serine degradation has been linked to NMDAR hypofunction and schizophrenia susceptibility, which is why hDAAO has been a target for antipsychotic drug development. The reaction requires one molecule of FAD (flavin adenine dinucleotide, a redox-active cofactor) per 40 kDa subunit; the FAD-bound, catalytically active form is called the holoenzyme, while the cofactor-free form is the apoprotein. Unlike DAAOs from other organisms, human DAAO is a stable homodimer even in the apoprotein form and shows the weakest interaction with free FAD of any known DAAO: the dissociation constant is about 8 μM8\,\mu\mathrm{M} (versus about 0.2 μM0.2\,\mu\mathrm{M} for the pig kidney enzyme), tightened roughly 20-fold to about 0.4 μM0.4\,\mu\mathrm{M} when an active-site ligand such as the substrate analogue benzoate is bound. Crystal structures of hDAAO solved since 2006 (for example Protein Data Bank (PDB) entries 2DU8 and 2E48) are all of the FAD-containing holoenzyme; no structure of the cofactor-free apoprotein has been obtained. Biochemically, the apoprotein is distinguished by a more open tertiary structure, higher protein fluorescence, larger exposure of hydrophobic surfaces, and higher sensitivity to proteolysis, and later work showed the apoprotein itself exists in two conformations differing in FAD affinity. Reconstitution is a sequential process: FAD binds rapidly to give an intermediate (Holo*) in which flavin fluorescence is quenched and activity is recovered, and a subsequent slower conformational rearrangement (>60 min at 15 degrees C, detectable only by protein fluorescence) generates the final holoenzyme. Because overall brain FAD concentration is estimated at about 5 μM5\,\mu\mathrm{M} — close to the KdK_d — and D-serine concentrations (roughly 6 μM6\,\mu\mathrm{M} in forebrain extracellular fluid, about 300 μM300\,\mu\mathrm{M} overall) are far below the KmK_m of about 7.5 mM7.5\,\mathrm{mM}, hDAAO was proposed to be largely in the inactive apoprotein form in vivo, with holoenzyme formation promoted by active-site ligands; this has been suggested as a built-in mechanism preventing excessive depletion of the neuromodulator. Two physiological complications frame the open questions. First, cellular compartmentation (hDAAO is peroxisomal, but newly synthesized enzyme transits the cytosol), local microenvironments, and binding partners could shift this equilibrium in ways not captured by bulk concentrations. Second, hDAAO specifically interacts with pLG72, the product of the primate-specific G72 gene that has been genetically associated with schizophrenia: pLG72 binding produces a time-dependent loss of hDAAO activity through alteration of its tertiary structure without changing its kinetic parameters or FAD affinity, and in glial cells it shortens the enzyme's half-life. The 2009 study that established the weak-flavin-binding picture left unresolved: the apoprotein structure, the in vivo holo/apo fraction, the identity of endogenous ligands that tighten FAD binding, the molecular nature of the slow Holo*-to-holoenzyme isomerization, and the mechanism of pLG72-accelerated inactivation; these jointly define how weak cofactor binding is used to regulate hDAAO activity inside the cell.

Problem Statement

Determine how weak FAD cofactor binding regulates human D-amino acid oxidase in the cell, connecting the established in vitro biophysical picture to the in vivo regulation of D-serine metabolism. The common objective is a quantitative cellular account of hDAAO cofactor occupancy and of the factors that set the level of active hDAAO in the cell, as posed by the source literature (Caldinelli et al. 2009, doi:10.1002/pro.86) and still not fully resolved. The five components below form one physiological question — what sets the level of active hDAAO in the cell — and bear on that level, on the available structural and biochemical evidence, as follows: components (1)–(3) directly through cofactor occupancy, component (4) through the post-binding maturation state, and component (5) through the total amount of active enzyme, rather than only through the holoenzyme/apoprotein fraction. A quantitative estimate of the holoenzyme/apoprotein fraction under cellular conditions is the central target of this account, and several components cannot yet be settled because the needed apoprotein structure, endogenous ligand, or in vivo occupancy measurement does not exist. The components, to be treated as open questions, are: (1) the three-dimensional structure of the apoprotein form, in particular the open flavin pocket and the exposed hydrophobic surfaces, which has not yet been obtained experimentally; (2) the fraction of active holoenzyme versus inactive apoprotein under cellular conditions — the central question itself rather than one item among several, given estimated brain FAD concentrations close to the in vitro KdK_d and D-serine concentrations far below the KmK_m, and accounting for compartmentation, local microenvironments, and binding partners such as pLG72; (3) which endogenous active-site ligands or modulators, beyond tested substrate analogues such as benzoate, tighten FAD binding and thereby trigger holoenzyme formation in brain, and at what physiological concentrations; (4) the molecular nature of the slow conformational isomerization step from the Holo* intermediate to the final holoenzyme observed on the timescale of tens of minutes at 15 degrees C; and (5) how pLG72 interaction accelerates hDAAO inactivation in cells — the cellular-level pathway (tertiary-structure destabilization and accelerated proteasomal degradation of cytosolic hDAAO, with unchanged FAD affinity) being established, the remaining open question is the atomic/molecular mechanism, for which no experimental structure of pLG72 or of the hDAAO-pLG72 complex exists.

References

  1. Caldinelli L, Molla G, Sacchi S, Pilone MS, Pollegioni L (2009). Relevance of weak flavin binding in human D-amino acid oxidase. Protein Science 18(4):801-810. doi:10.1002/pro.86. https://doi.org/10.1002/pro.86
  2. Sacchi S, Bernasconi M, Martineau M, Mothet J-P, Ruzzene M, Pilone MS, Pollegioni L, Molla G (2008). pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. Journal of Biological Chemistry 283(32):22244-22256. doi:10.1074/jbc.M709153200. https://doi.org/10.1074/jbc.M709153200
  3. Caldinelli L, Molla G, Bracci L, Lelli B, Pileri S, Cappelletti P, Sacchi S, Pollegioni L (2010). Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Protein Science 19(8):1500-1512. doi:10.1002/pro.429. https://doi.org/10.1002/pro.429
  4. Sacchi S, Cappelletti P, Giovannardi S, Pollegioni L (2011). Evidence for the interaction of D-amino acid oxidase with pLG72 in a glial cell line. Molecular and Cellular Neuroscience 48(1):20-28. doi:10.1016/j.mcn.2011.06.001. https://doi.org/10.1016/j.mcn.2011.06.001
  5. Frattini LF, Piubelli L, Sacchi S, Molla G, Pollegioni L (2011). Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase. FEBS Journal 278(22):4362-4373. doi:10.1111/j.1742-4658.2011.08354.x. https://doi.org/10.1111/j.1742-4658.2011.08354.x
  6. Murtas G, Sacchi S, Valentino M, Pollegioni L (2017). Biochemical Properties of Human D-amino Acid Oxidase. Frontiers in Molecular Biosciences 4:88. doi:10.3389/fmolb.2017.00088. https://doi.org/10.3389/fmolb.2017.00088
  7. Birolo L, Sacchi S, Smaldone G, Molla G, Leo G, Caldinelli L, Pirone L, Eliometri P, Di Gaetano S, Orefice I, Pedone E, Pucci P, Pollegioni L (2016). Regulating levels of the neuromodulator d-serine in human brain: structural insight into pLG72 and d-amino acid oxidase interaction. FEBS Journal 283(18):3353-3370. doi:10.1111/febs.13809. https://doi.org/10.1111/febs.13809
  8. Cappelletti P, Campomenosi P, Pollegioni L, Sacchi S (2014). The degradation (by distinct pathways) of human D-amino acid oxidase and its interacting partner pLG72--two key proteins in D-serine catabolism in the brain. FEBS Journal 281(3):708-723. doi:10.1111/febs.12616. https://doi.org/10.1111/febs.12616
  9. Pollegioni L, Piubelli L, Molla G, Rosini E (2018). D-Amino Acid Oxidase-pLG72 Interaction and D-Serine Modulation. Frontiers in Molecular Biosciences 5:3. doi:10.3389/fmolb.2018.00003. https://doi.org/10.3389/fmolb.2018.00003
  10. Pollegioni L, Sacchi S, Murtas G (2018). Human D-Amino Acid Oxidase: Structure, Function, and Regulation. Frontiers in Molecular Biosciences 5:107. doi:10.3389/fmolb.2018.00107. https://doi.org/10.3389/fmolb.2018.00107
  11. Murtas G, Pollegioni L, Molla G, Sacchi S (2022). Biochemical Properties and Physiological Functions of pLG72: Twenty Years of Investigations. Biomolecules 12(6):858. doi:10.3390/biom12060858. https://doi.org/10.3390/biom12060858
  12. Rabattoni V, Motta Z, Miceli M, Molla G, Fissore A, Adinolfi S, Pollegioni L, Sacchi S (2023). On the regulation of human D-aspartate oxidase. Protein Science 32(11):e4802. doi:10.1002/pro.4802. https://doi.org/10.1002/pro.4802
  13. Maffioli E, Errico F, Motta Z, di Vito R, Grana J, De Grandis E, Boeri S, Bruno C, Riccio MP, Iasevoli F, Di Maio M, Nuzzo T, Bravaccio C, Bagnasco S, Gelzo M, Castaldo G, de Bartolomeis A, Negri A, Pollegioni L, Tedeschi G, Usiello A (2026). Blood levels of D-aspartate oxidase, D-amino acid oxidase, serine racemase, and pLG72 are influenced by diagnoses of schizophrenia and autism spectrum disorder. Schizophrenia (Heidelberg) 12(1):58. doi:10.1038/s41537-026-00758-7. https://doi.org/10.1038/s41537-026-00758-7
  14. Kawazoe T, Tsuge H, Pilone MS, Fukui K (2006). Crystal structure of human D-amino acid oxidase: context-dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si-face of the flavin ring. Protein Science 15(12):2708-2717. doi:10.1110/ps.062421606. https://doi.org/10.1110/ps.062421606